Dechra Pharm FY Group Rev Up 5.3% Yr On Yr, In line With Views

7th Jul 2010 07:34

LONDON (Dow Jones)--Dechra Pharmaceuticals PLC (DPH.LN), announced Wednesday for the year ended June 30, Group revenue was 5.3% ahead of the equivalent period last year and the Group continues to perform robustly and in line with management views. MAIN FACTS: -The company remains confident about future growth prospects. -Although the company's markets have experienced slower rates of growth than historical levels, it has demonstrated solid progress compared to last year. -In European pharmaceuticals, revenue increased by 9.0% compared to last year with both specialist pet diets and pharmaceuticals showing solid growth. -Foreign currency fluctuations did not have a material impact on these numbers. -Its manufacturing business, Dales Pharmaceuticals, performed well during the period due to improved efficiency and increased production of both its own and third party products. -In U.S. pharmaceuticals, overall revenue was 36.6% higher than last year. -Revenue from U.S. Vetoryl in the period was $6.6 million. -In its Services division revenue grew by 3.3% compared to last year. -Operating cash flow during the period was strong, resulting in a further reduction in net borrowings. -Shares closed Tuesday at 415 pence. -By Zechariah Hemans, Dow Jones Newswires; 44-20-7842-9411; [email protected] (END) Dow Jones Newswires July 07, 2010 02:34 ET (06:34 GMT)